Rezk Mourad F, Pieper Burkhard
Biogen International GmbH, Zug, Switzerland.
Rheumatol Ther. 2017 Dec;4(2):209-218. doi: 10.1007/s40744-017-0085-z. Epub 2017 Oct 14.
Over the years, biologic agents have proven their importance in the management of chronic autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Biosimilars, which are biologic medicines, are highly similar to approved biologic medicines, and are comprehensively developed and rigorously tested to ensure efficacy and safety are similar to the reference product. A broader armamentarium of biosimilars is expected to improve patients' access to safe and effective biologic medicines, thus offering benefits to healthcare systems around the globe. Here we consider the factors that may compromise the benefits of biosimilars being realized, including patient and physician perception of biosimilars, and an often overlooked factor, the nocebo effect, which is re-emerging with the widespread adoption of biosimilar medicines. We have also described a variety of strategies and recommendations that could help limit the nocebo effect.
Biogen.
多年来，生物制剂已证明其在治疗类风湿性关节炎、银屑病和炎症性肠病等慢性自身免疫性疾病中的重要性。生物类似药作为生物药物，与已获批的生物药物高度相似，并且经过全面研发和严格测试，以确保其疗效和安全性与参比产品相似。预计更广泛的生物类似药种类将改善患者获得安全有效生物药物的机会，从而为全球医疗保健系统带来益处。在此，我们探讨了可能影响生物类似药益处实现的因素，包括患者和医生对生物类似药的认知，以及一个常被忽视的因素——安慰剂效应，随着生物类似药的广泛应用，该效应再次出现。我们还描述了多种有助于限制安慰剂效应的策略和建议。
百健公司。
